ClassID:

96976

C07K14/55 - page 3 - CPC Classification

Classification description:

Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Cytokines; Lymphokines; Interferons; Interleukins [IL] IL-2

Recent Application in this class:
#601
20210213102
2021-07-15

NOVEL INTERLEUKIN-2 AND USE THEREOF

#602
20210206830
2021-07-08

Methods for modulating an immune response

#603
20210198342
2021-07-01

FC-EPSILON CAR (Very imp commercially - in clinical trial)

#604
20210198337
2021-07-01

T-cell modulatory multimeric polypeptides and methods of use thereof

#605
20210198336
2021-07-01

IL-2R-βγ binding compounds

#606
20210196796
2021-07-01

IL-2 orthologs and methods of use

#607
20210196771
2021-07-01

RECOMBINANT MYXOMA VIRUSES AND USES THEREOF

#608
20210188934
2021-06-24

NOVEL IL2 AGONISTS AND METHODS OF USE THEREOF

#609
20210187027
2021-06-24

IL2 and peptide-MHC complex fusion proteins and methods of use thereof

#610
20210187025
2021-06-24

SUBSETS OF HUMAN NATURAL KILLER CELLS WITH ENHANCED ANTIBODY-DIRECTED IMMUNE RESPONSES

#611
20210180067
2021-06-17

NUCLEIC ACID APTAMERS

#612
20210177988
2021-06-17

IMMUNOREACTANT CARRIER

#613
20210177983
2021-06-17

SINGLE CHAIN Fc FUSION PROTEINS

#614
20210163892
2021-06-03

Generating HPV antigen-specific cells from a naive T cell population

#615
20210163565
2021-06-03

Cytokine fusion proteins, and their pharmaceutical compositions and therapeutic applications

#616
20210155900
2021-05-27

Generating HPV antigen-specific cells from a naive T cell population

#617
20210155665
2021-05-27

METHOD FOR PREPARING INTERLEUKIN-2 OR INTERLEUKIN-2 ANALOGUES

#618
20210147871
2021-05-20

Viral vectors and packaging cell lines

#619
20210139554
2021-05-13

Interleukin-2 muteins for the expansion of T-regulatory cells

#620
20210139553
2021-05-13

Cytokine-based bioactivatable drugs and methods of uses thereof

#621
20210138008
2021-05-13

RECOMBINANT ONCOLYTIC VIRUS COMPOSITION AND USE THEREOF

#622
20210130467
2021-05-06

Immunotherapeutic tumor treatment method

#623
20210115102
2021-04-22

SEPARATION MOIETIES AND METHODS OF USE THEREOF

#624
20210114999
2021-04-22

TARGETING STAT SUMOYLATION TO ENHANCE IMMUNE RESPONSES

#625
20210113606
2021-04-22

TREATMENT USING CYTOKINE ENCODING RNA

#626
20210107962
2021-04-15

T-cell modulatory multimeric polypeptides and methods of use thereof

#627
20210101953
2021-04-08

Human Interleukin-2 and Anti-human Epithelial Cell Adhesion Molecule Single-Chain Antibody Fusion Protein and Application Thereof

#628
20210095017
2021-04-01

Methods for treating vascular leak syndrome and cancer

#629
20210094997
2021-04-01

Interleukin-2 muteins for the expansion of T-regulatory cells

#630
20210094996
2021-04-01

Targeted immunotolerance

#631
20210094995
2021-04-01

METHODS AND COMPOSITIONS FOR TREATING CANCER WITH ECM-AFFINITY PEPTIDES LINKED TO CYTOKINES

#632
20210079102
2021-03-18

COMBINATION THERAPY OF CANCER INVOLVING MULTI-SPECIFIC BINDING PROTEINS THAT ACTIVATE NATURAL KILLER CELLS

#633
20210079055
2021-03-18

Superagonists, partial agonists and antagonists of interleukin-2

#634
20210070857
2021-03-11

Immune cells engineered to express CD19-directed chimeric antigen receptors and uses thereof in immunotherapy

#635
20210070856
2021-03-11

CD19-directed chimeric antigen receptors and uses thereof in immunotherapy

#636
20210070828
2021-03-11

MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES

#637
20210070827
2021-03-11

Il-2 conjugates and methods of use to treat autoimmune diseases

#638
20210069243
2021-03-11

Biologically relevant orthogonal cytokine/receptor pairs

#639
20210063382
2021-03-04

METHOD AND SYSTEM FOR SCREENING ANTI-TUMOUR SUBSTANCES

#640
20210061878
2021-03-04

HIGH AFFINITY NY-ESO T CELL RECEPTORS

#641
20210060073
2021-03-04

Cancer immunotherapy using CD19-directed chimeric antigen receptors

#642
20210060068
2021-03-04

BIOLOGICALLY RELEVANT ORTHOGONAL CYTOKINE/RECEPTOR PAIRS

#643
20210054095
2021-02-25

Antibodies to tumour antigens

#644
20210054084
2021-02-25

Anti-CD25 antibody agents

#645
20210052727
2021-02-25

Cytokine fusion proteins

#646
20210047382
2021-02-18

MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES

#647
20210038659
2021-02-11

COMBINATION THERAPY USING A CHIMERIC ANTIGEN RECEPTOR

#648
20210032306
2021-02-04

Compositions and methods for targeted cytokine delivery

#649
20210024631
2021-01-28

BI-FUNCTIONAL PROTEINS AND CONSTRUCTION THEREOF

#650
20210024602
2021-01-28

IL-2 Conjugates

#651
20210024601
2021-01-28

Interleukin-2 agents and uses thereof

#652
20210023230
2021-01-28

CONJUGATES OF AN IL-2 MOIETY AND A POLYMER

#653
20210015864
2021-01-21

Chimeric transmembrane proteins and uses thereof

#654
20210009704
2021-01-14

Anti-CD25 for tumour specific cell depletion

#655
20210009703
2021-01-14

Anti-CD25 for tumour specific cell depletion

#656
20210009702
2021-01-14

Anti-CD25 for tumour specific cell depletion

#657
20210009699
2021-01-14

Anti-CD25 antibody agents

#658
20210002343
2021-01-07

Masked cytokine polypeptides

#659
20200407454
2020-12-31

Anti-CD25 antibody agents

#660
20200407416
2020-12-31

Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use Thereof

#661
20200399615
2020-12-24

Enhanced adoptive cell therapy

#662
20200392457
2020-12-17

METHODS OF PRODUCING MODIFIED NATURAL KILLER CELLS AND METHODS OF USE

#663
20200390816
2020-12-17

METHODS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND USES THEREOF

#664
20200390812
2020-12-17

Method for NK cell transduction

#665
20200385438
2020-12-10

Engineered proteins to enhance sensitivity of a cell to IL-2

#666
20200376033
2020-12-03

ELIMINATION OF CD19-POSITIVE LYMPHOID MALIGNANCIES BY CD19-CAR EXPRESSING NK CELLS

#667
20200369740
2020-11-26

Fusion protein comprising IL-2 protein and CD80 protein, and use thereof

#668
20200362014
2020-11-19

APPLICATIONS OF SOLUBLE PROTEIN BAFF IN B CELL IN-VITRO CULTURE AND PROLIFERATION

#669
20200347351
2020-11-05

Modified NK-92 haNK003 cells for the clinic

#670
20200347109
2020-11-05

De novo design of potent and selective interleukin mimetics

#671
20200345775
2020-11-05

Method of treating glioblastoma multiforme

#672
20200339648
2020-10-29

De novo design of potent and selective interleukin mimetics

#673
20200339624
2020-10-29

MODULATION OF T CELLS WITH BISPECIFIC ANTIBODIES AND FC FUSIONS

#674
20200331982
2020-10-22

Methods for modulating an immune response

#675
20200330534
2020-10-22

Expression of metabolic modulators in tumor microenvironment to improve tumor therapy

#676
20200325205
2020-10-15

Methods for modulating an immune response

#677
20200325202
2020-10-15

IL-2 muteins and uses thereof

#678
20200325201
2020-10-15

IL-2 muteins and uses thereof

#679
20200317744
2020-10-08

De novo design of potent and selective interleukin mimetics

#680
20200316118
2020-10-08

Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity

#681
20200299349
2020-09-24

PARTIAL AGONISTS OF INTERLEUKIN-2

#682
20200291091
2020-09-17

Compositions and methods for immunomodulation in an organism

#683
20200283498
2020-09-10

T CELL RECEPTOR FUSIONS AND CONJUGATES AND METHODS OF USE THEREOF

#684
20200283490
2020-09-10

Activatable interleukin-2 polypeptides and methods of use thereof

#685
20200270334
2020-08-27

Antibody-IL2 engrafted proteins and methods of use in the treatment of cancer

#686
20200270324
2020-08-27

SIRP-gamma polypeptide compositions and treatment of cancer

#687
20200270322
2020-08-27

NOVEL INTERLEUKIN 4 IMMUNOCONJUGATES

#688
20200263196
2020-08-20

METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS

#689
20200231644
2020-07-23

Cytokine conjugates for the treatment of autoimmune diseases

#690
20200207824
2020-07-02

T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF

#691
20200199189
2020-06-25

Cytokine combination

#692
20200199181
2020-06-25

T-cell modulatory multimeric polypeptides and methods of use thereof

#693
20200190220
2020-06-18

Circular tandem repeat proteins

#694
20200188484
2020-06-18

Cytokine conjugates for the treatment of proliferative and infectious diseases

#695
20200188433
2020-06-18

aNK AND IL-12 COMPOSITIONS AND METHODS

#696
20200181220
2020-06-11

CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES

#697
20200172594
2020-06-04

T CELL RECEPTOR FUSIONS AND CONJUGATES AND METHODS OF USE THEREOF

#698
20200172591
2020-06-04

Interleukin-2 fusion proteins and uses thereof

#699
20200157166
2020-05-21

Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses

#700
20200148737
2020-05-14

Therapeutic compounds and methods

#701
20200131262
2020-04-30

Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer infections and autoimmune disorders

#702
20200131240
2020-04-30

USE OF IL-12 TO GENERATE ENDOGENOUS ERYTHROPOIETIN

#703
20200129553
2020-04-30

Elimination of CD19-positive lymphoid malignancies by CD19-CAR expressing NK cells

#704
20200129552
2020-04-30

Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells

#705
20200115429
2020-04-16

Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases

#706
20200101111
2020-04-02

Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies

#707
20200101110
2020-04-02

Kinase mutants and uses thereof

#708
20200093863
2020-03-26

Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies

#709
20200087369
2020-03-19

THERAPEUTIC COMPOUNDS AND METHODS

#710
20200085872
2020-03-19

Immune cells expressing engineered antigen receptors

#711
20200055953
2020-02-20

Method for Treating a GD2 Positive Cancer

#712
20200040101
2020-02-06

Antibodies and methods for making and using the same

#713
20200040080
2020-02-06

Fusion protein for restoring the functions of failing immune cells and application thereof

#714
20200040053
2020-02-06

Ligands Modified by Circular Permutation as Agonists and Antagonists

#715
20200040052
2020-02-06

Activatable interleukin-2 polypeptides

#716
20200038441
2020-02-06

Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies

#717
20200031897
2020-01-30

Multivalent regulatory T cell modulators

#718
20200024338
2020-01-23

Compositions comprising R-Spondin (RSPO) surrogate molecules

#719
20200024319
2020-01-23

Interleukin-2 muteins for the expansion of T-regulatory cells

#720
20200010554
2020-01-09

Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody

#721
20200010547
2020-01-09

Combination of an anti-CD16A antibody with a cytokine

#722
20200010528
2020-01-09

METHODS FOR MODULATING AN IMMUNE RESPONSE

#723
20200002727
2020-01-02

MULTI-SITE SPECIFIC INTEGRATION CELLS FOR DIFFICULT TO EXPRESS PROTEINS

#724
20200002398
2020-01-02

De novo design of potent and selective interleukin mimetics

#725
20190375812
2019-12-12

MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES

#726
20190374609
2019-12-12

COMBINATION THERAPY OF TUMOR-TARGETED IL-2 VARIANT IMMUNOCYTOKINES AND ANTIBODIES AGAINST HUMAN PD-L1

#727
20190361018
2019-11-28

Materials and methods relating to dosage regimen design

#728
20190359672
2019-11-28

Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use

#729
20190352402
2019-11-21

Antibody binding PD-1 and use thereof

#730
20190352382
2019-11-21

IMMUNE CHECKPOINT THERAPY

#731
20190352363
2019-11-21

T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF

#732
20190350981
2019-11-21

METHODS OF TREATING MULTIPLE SCLEROSIS USING AUTOLOGOUS T CELLS

#733
20190345257
2019-11-14

RP215 chimeric antigen receptor construct and methods of making and using same

#734
20190343925
2019-11-14

Synergistic tumor treatment with an extended pharmacokinetic IL-2 and integrin-binding-Fc fusion protein

#735
20190338032
2019-11-07

Anti-PD-L1 and IL-2 cytokines

#736
20190330351
2019-10-31

ANTI-PD-L1 ANTIBODIES

#737
20190330345
2019-10-31

Anti-ICOS antibodies

#738
20190322765
2019-10-24

MUTANT INTERLEUKIN-2 POLYPEPTIDES

#739
20190322763
2019-10-24

NOVEL IMMUNOCONJUGATES

#740
20190322752
2019-10-24

Anti-CD25 antibody agents

#741
20190315883
2019-10-17

Immunoconjugates

#742
20190315826
2019-10-17

Method for increasing the secretion levels of interleukin 2 and muteins thereof by introducing a point mutation

#743
20190300854
2019-10-03

Modified NK-92 haNK003 cells for the clinic

#744
20190300613
2019-10-03

Anti-CD25 antibody agents

#745
20190300592
2019-10-03

Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use

#746
20190284287
2019-09-19

Anti-CD25 antibody agents

#747
20190284253
2019-09-19

IL2 and TNF immunoconjugates

#748
20190270788
2019-09-05

CHEMOKINE-CYTOKINE FUSION PROTEINS AND THEIR APPLICATIONS

#749
20190270787
2019-09-05

CYSTEINE VARIANTS OF INTERLEUKIN-11 AND METHODS OF USE THEREOF

#750
20190269807
2019-09-05

SOLUBLE TCR MOLECULES AND METHODS OF USE

#751
20190269729
2019-09-05

Modified natural killer cells for the treatment of cancer

#752
20190263877
2019-08-29

IL-15 variants and uses thereof

#753
20190262400
2019-08-29

ARTIFICIAL ANTIGEN PRESENTING CELLS FOR EXPANDING IMMUNE CELLS FOR IMMUNOTHERAPY

#754
20190255150
2019-08-22

Fusion proteins with extended serum half life

#755
20190248860
2019-08-15

Superagonists and antagonists of interleukin-2

#756
20190241638
2019-08-08

Engineered IL-2 Fc fusion proteins

#757
20190225710
2019-07-25

Multimers, tetramers and octamers

#758
20190202917
2019-07-04

MULTISPECIFIC ANTIBODIES FOR IMMUNO-ONCOLOGY

#759
20190202882
2019-07-04

Nucleic acid encoding human IL-2 variant

#760
20190202881
2019-07-04

Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases

#761
20190185821
2019-06-20

GENE THERAPY VECTORS AND CYTOSINE DEAMINASES

#762
20190183933
2019-06-20

Biologically relevant orthogonal cytokine/receptor pairs

#763
20190177409
2019-06-13

Methods for treating vascular leak syndrome and cancer

#764
20190175650
2019-06-13

Methods for expanding and activating γδ T cells for the treatment of cancer and related malignancies

#765
20190169255
2019-06-06

IL-2 MUTEINS AND USES THEREOF

#766
20190169254
2019-06-06

IL-2 MUTEINS AND USES THEREOF

#767
20190160115
2019-05-30

Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells

#768
20190153058
2019-05-23

Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases

#769
20190136240
2019-05-09

Nucleic acid aptamers

#770
20190134095
2019-05-09

COMPOSITIONS AND METHODS FOR IMPROVED NK CELL THERAPIES

#771
20190127451
2019-05-02

Non-glycosylated anti-tenascin antibody

#772
20190119346
2019-04-25

Method of treating graft versus host disease with an interleukin-2 mutein

#773
20190119345
2019-04-25

Compositions and methods for targeted cytokine delivery

#774
20190092831
2019-03-28

Compositions and methods for targeted cytokine delivery

#775
20190077881
2019-03-14

Mutant interleukin-2 polypeptides

#776
20190071472
2019-03-07

Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses

#777
20190070263
2019-03-07

Modulating gamma-c-cytokine activity

#778
20190062395
2019-02-28

IL-2 superagonists in combination with anti-PD-1 antibodies

#779
20190056392
2019-02-21

METHODS FOR THE DIAGNOSTIC OF AN AUTOIMMUNE DISEASE

#780
20190046664
2019-02-14

Immunostimulating vector system

#781
20190023760
2019-01-24

METHOD FOR PREPARING INTERLEUKIN-2 OR INTERLEUKIN-2 ANALOGUES

#782
20190016797
2019-01-17

Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof

#783
20190016796
2019-01-17

COMBINATION THERAPY COMPRISING A SUPERAGONISTIC ANTIBODY AGAINST INTERLEUKIN-2 AND A CHECKPOINT BLOCKADE AGENT

#784
20190008978
2019-01-10

Method of refolding an interleukin-2 (IL-2) protein

#785
20190002915
2019-01-03

COMPOSITIONS AND METHODS FOR REGULATABLE ANTIBODY EXPRESSION

#786
20190002590
2019-01-03

Circular tandem repeat proteins

#787
20190002516
2019-01-03

Drug Design Method, Obtained Drug and Application Thereof

#788
20180371049
2018-12-27

HIGH AFFINITY NY-ESO T CELL RECEPTORS

#789
20180369280
2018-12-27

High affinity T cell receptors and uses thereof

#790
20180340014
2018-11-29

Targeted immunotolerance

#791
20180334491
2018-11-22

Variant serum albumin with improved half-life and other properties

#792
20180326010
2018-11-15

Immunoconjugates

#793
20180319859
2018-11-08

Interleukin-2 muteins for the expansion of T-regulatory cells

#794
20180312807
2018-11-01

Generating HPV antigen-specific cells from a naive T cell population

#795
20180298079
2018-10-18

Compositions and methods for immunomodulation in an organism

#796
20180291089
2018-10-11

SECRETORY TNT CAR CELL IMMUNOTHERAPY

#797
20180289825
2018-10-11

Single chain Fc fusion proteins

#798
20180282386
2018-10-04

Therapeutic compounds and methods

#799
20180258397
2018-09-13

Modified NK-92 haNK003 cells for the clinic

#800
20180237489
2018-08-23

Interleukin-2 muteins for the expansion of T-regulatory cells

#801
20180237488
2018-08-23

Method for producing interleukin-2 protein using methylotrophic yeast

#802
20180228842
2018-08-16

Biologically relevant orthogonal cytokine/receptor pairs

#803
20180222959
2018-08-09

Exposed collagen-targeted fusion cytokine for immune modulation in invasive cancers and lesions of infections

#804
20180200338
2018-07-19

COMBINATION THERAPY OF TUMOR-TARGETED IL-2 VARIANT IMMUNOCYTOKINES AND ANTIBODIES AGAINST HUMAN PD-L1

#805
20180187210
2018-07-05

Non-HLA matched humanized NSG mouse model with patient-derived xenograft

#806
20180162919
2018-06-14

Multivalent regulatory T cell modulators

#807
20180155405
2018-06-07

SIRP-gamma polypeptide compositions and methods of use

#808
20180142037
2018-05-24

Mutant interleukin-2 polypeptides

#809
20180134801
2018-05-17

Method for treating a GD2 positive cancer

#810
20180125941
2018-05-10

IL-2 variants for the treatment of psoriasis

#811
20180086810
2018-03-29

T CELL RECEPTOR FUSIONS AND CONJUGATES AND METHODS OF USE THEREOF

#812
20180085468
2018-03-29

Conjugates of an IL-2 moiety and a polymer

#813
20180079793
2018-03-22

IL2 and TNF immunoconjugates

#814
20180072990
2018-03-15

GENERATING VIRUS OR OTHER ANTIGEN-SPECIFIC T CELLS FROM A NAÏVE T CELL POPULATION

#815
20180072788
2018-03-15

HIGH AFFINITY NY-ESO T CELL RECEPTORS

#816
20180066058
2018-03-08

Anti-ICOS antibodies

#817
20180044424
2018-02-15

Car-expressing cells against multiple tumor antigens and uses thereof

#818
20180037624
2018-02-08

Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases

#819
20180030123
2018-02-01

METHOD FOR TREATING A TUMOR WITH BIFUNCTIONAL AGENTS THAT BIND TO TUMOR CARBOHYDRATE ANTIGENS

#820
20180030106
2018-02-01

Interleukin-2 expression construct using human serium albumin

#821
20180016317
2018-01-18

Methods for treating inflammation with fusion proteins comprising interleukin-2 and interleukin-33

#822
20180009890
2018-01-11

Methods for treating vascular leak syndrome and cancer

#823
20180009868
2018-01-11

Interleukin-2 fusion proteins and uses thereof

#824
20170369547
2017-12-28

Method to increase the number of circulating platelets by administering PEGylated cysteine variants of IL-11

#825
20170368169
2017-12-28

Multispecific and multifunctional molecules and uses thereof

#826
20170368138
2017-12-28

Method of treating cancer with a multiple integrin binding Fc fusion protein

#827
20170362321
2017-12-21

Antibodies and immunocytokines

#828
20170333573
2017-11-23

Methods and compositions relating to improved lentiviral vectors and their applications

#829
20170333479
2017-11-23

Methods and compositions for natural killer cells

#830
20170327555
2017-11-16

MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES

#831
20170327554
2017-11-16

Chemokine-cytokine fusion proteins of SDF-1 and CD40L

#832
20170320933
2017-11-09

Cytokine-based fusion proteins for treatment of immune disorders

#833
20170313753
2017-11-02

Method of promoting regulatory T-cell proliferation

#834
20170283810
2017-10-05

Nucleic acid constructs for presentation of CD4 and CD8 epitopes, cellular transfection and uses thereof

#835
20170233448
2017-08-17

Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use

#836
20170224734
2017-08-10

Tumor infiltrating cells engineered to express a pro-inflammatory polypeptide

#837
20170216402
2017-08-03

Synergistic tumor treatment with antibodies targeting PD-1, PD-L1 or CTLA4 and integrin-binding-Fc-fusion protein

#838
20170204154
2017-07-20

MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES

#839
20170183403
2017-06-29

Immune-stimulating monoclonal antibodies against human interleukin-2

#840
20170137786
2017-05-18

Enhanced adoptive cell therapy

#841
20170137485
2017-05-18

Interleukin-2 muteins for the expansion of T-regulatory cells

#842
20170096472
2017-04-06

ALBUMIN FUSION PROTEINS

#843
20170088631
2017-03-30

Immunoconjugates

#844
20170088599
2017-03-30

High affinity NY-ESO T cell receptors

#845
20170081382
2017-03-23

Interleukin-2 muteins for the expansion of T-regulatory cells

#846
20170080104
2017-03-23

Cell surface coupling of nanoparticles

#847
20170073387
2017-03-16

Compositions of GM-CSF and interleukin fusions for immune modulation and uses related thereto

#848
20170067079
2017-03-09

METHODS AND COMPOSITIONS RELATING TO RESTRICTED EXPRESSION LENTIVIRAL VECTORS AND THEIR APPLICATIONS

#849
20170051029
2017-02-23

MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES

#850
20170045512
2017-02-16

IL-2 peptide derivatives, and uses thereof for the diagnosis and treatment of an autoimmune disease

#851
20170044229
2017-02-16

Superagonists, partial agonists and antagonists of interleukin-2

#852
20170044228
2017-02-16

Ligands modified by circular permutation as agonists and antagonists

#853
20170037102
2017-02-09

MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES

#854
20170015722
2017-01-19

Superagonists and antagonists of interleukin-2

#855
20170000886
2017-01-05

MESENCHYMAL STEM CELLS FOR TARGETED CANCER THERAPY

#856
20160375152
2016-12-29

Methods and compositions relating to improved lentiviral vectors and their applications

#857
20160375149
2016-12-29

IN VIVO TARGETING OF CELLS WITH LIGAND-CONJUGATED PARTICLES

#858
20160347818
2016-12-01

Compositions and methods for immunomodulation in an organism

#859
20160340406
2016-11-24

Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules

#860
20160340397
2016-11-24

SIRP polypeptide compositions and methods of use

#861
20160333067
2016-11-17

Compositions and methods for immunomodulation in an organism

#862
20160304574
2016-10-20

Fusion protein comprising interleukin-2 and interleukin-33

#863
20160287671
2016-10-06

Boosting Treg cells for treating Alzheimer disease and related disorders

#864
20160263240
2016-09-15

Immunoconjugates

#865
20160237132
2016-08-18

Fusion polypeptides comprising mucin-domain polypeptide linkers

#866
20160229901
2016-08-11

Interleukin-2 fusion proteins and uses thereof

#867
20160208017
2016-07-21

Mutant interleukin-2 polypeptides

#868
20160175458
2016-06-23

SINGLE CHAIN FC FUSION PROTEINS

#869
20160152687
2016-06-02

ALBUMIN FUSION PROTEINS

#870
20160145654
2016-05-26

POLYMER PARTICLES AND USES THEREOF

#871
20160090407
2016-03-31

INTERLEUKIN-2 FUSION PROTEINS AND USES THEREOF

#872
20160068862
2016-03-10

Methods and compositions relating to improved lentiviral vectors and their applications

#873
20160052983
2016-02-25

Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide

#874
20160039920
2016-02-11

Methods of treating a neoplastic disease

#875
20160030526
2016-02-04

Bivalent IL-2 fusion toxins

#876
20160009768
2016-01-14

Modified toxins

#877
20150329619
2015-11-19

Albumin fusion proteins

#878
20150307577
2015-10-29

CHEMOKINE-CYTOKINE FUSION PROTEINS AND THEIR APPLICATIONS

#879
20150232880
2015-08-20

Enhanced adoptive cell therapy

#880
20150231233
2015-08-20

METHOD AND SYSTEM TO REMOVE SOLUBLE TNFR1, TNFR2, AND IL2 IN PATIENTS

#881
20150218260
2015-08-06

Interleukin-2 fusion proteins and uses thereof

#882
20150203568
2015-07-23

Albumin fusion proteins

#883
20150139945
2015-05-21

Compositions and methods for immunomodulation in an organism

#884
20150125421
2015-05-07

Cytokine-based fusion proteins for treatment of immune disorders

#885
20150093357
2015-04-02

Compositions and methods for Immunomodulation in an organism

#886
20150086506
2015-03-26

Alteration of cell membrane for new functions using IL-2 and streptavidin

#887
20150079025
2015-03-19

T CELL RECEPTOR FUSIONS AND CONJUGATES AND METHODS OF USE THEREOF

#888
20150044134
2015-02-12

Compositions, methods and kits for treatment of cancer and autoimmune diseases

#889
20150017120
2015-01-15

SYNERGISTIC TUMOR TREATMENT WITH EXTENDED-PK IL-2 AND ADOPTIVE CELL THERAPY

#890
20150010944
2015-01-08

Modified SAK gene for the production of recombinant proteins

#891
20140378656
2014-12-25

Soluble TCR molecules and methods of use

#892
20140343252
2014-11-20

Aglycosylated Fc-containing polypeptides with cysteine substitutions

#893
20140328791
2014-11-06

Conjugates of an IL-2 moiety and a polymer

#894
20140315817
2014-10-23

VARIANT SERUM ALBUMIN WITH IMPROVED HALF-LIFE AND OTHER PROPERTIES

#895
20140314709
2014-10-23

IL-2 derivative polypeptides

#896
20140294759
2014-10-02

Targeting regulatory T cells with heterodimeric proteins

#897
20140294758
2014-10-02

Light chain immunoglobulin fusion proteins and methods of use thereof

#898
20140294723
2014-10-02

Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart

#899
20140286898
2014-09-25

Interleukin-2 muteins for the expansion of T-regulatory cells

#900
20140286897
2014-09-25

Compositions comprising TL1A-Ig fusion protein for the regulation of T regulatory cells, and methods for their use